Mabion finalizes purchase of new Cytiva Xcellerex™ XDR bioreactors with conventional mixing technology

• Cytiva will manufacture and install a set of bioreactors at Mabion manufacturing facility, delivery of which is expected in Q3 2023, followed by installation, commissioning, qualification testing and equipment acceptance.
• The Xcellerex™ XDR bioreactor set is based on a technology using a conventional mixing system, as opposed to Mabion’s current orbital shaking technology, which will help achieve technological diversification, in line with Strategy 2023-2027 from April this year.
• The expansion of the panel of available bioreactor technologies will result in greater flexibility for Mabion in discussions with potential customers as part of the CDMO services offered, which will translate into strengthening the Company’s competitive position and enable it to reach new potential customers.
• Mabion intends to complete the modernization of its existing plant in Konstantynów Łódzki by the end of the year, which will result in increased production capacity and enable it to run different processes at the same time, as well as increase the flexibility of its offering.

We are pleased to announce that Mabion S.A. has recently finalized the purchase of new Cytiva Xcellerex™ XDR bioreactors with conventional mixing technology. The increase in free production capacity will significantly affect the company’s attractiveness on the biologics CDMO market.

The contract with Global Life Sciences Solutions Poland Sp. z o.o., a company in the group of the globally recognized and established Cytiva company, is for the manufacture, sale, delivery and installation of a set of bioreactors with conventional mixing technology for Mabion’s existing plant in Konstantynów Łódzki. The ordered set of bioreactors includes 7 units with a total capacity of 4,510 liters, with the two largest units having a capacity of 2,000 liters each. According to the contract, the bioreactors are to be delivered in mid-October this year. The net value of the contract is €3.2 million.

Currently, Mabion has two orbital shaking technology bioreactors with a capacity of 2,500 liters each at its Konstantynów Lodz plant. According to an addendum concluded on May 22, 2023 with Kühner AG of Switzerland, in the third quarter of this year, the partner will supply Mabion with two state-of-the-art bioreactors using orbital shaking technology with a capacity of 2,500 liters each, which will replace the bioreactors used so far. The value of the contract with Kühner AG is €1.8 million. By the end of the year, the Company will therefore have four modern commercial-scale bioreactors with a total capacity of nearly 10,000 liters: two orbital shaking bioreactors and two bioreactors with conventional mixing technology.

One of the key elements of the strategy is the technological diversification of the existing plant in Konstantynów Łódzki and retrofitting it with a set of bioreactors using conventional mixing technology, as part of the modernization that has begun. The goal is to increase the attractiveness of the CDMO’s service offering by providing greater flexibility and a more complete fit for potential customers, who will be able to use both the bioreactors with orbital shaking technology and the new bioreactors with conventional mixing technology.

Mabion is focused entirely on the CDMO area, where it has identified the greatest potential for business and financial growth. The company has a team of specialists and a state-of-the-art facility to meet the needs of small and medium-sized companies that are potential clients. The complete range of services offered, from the development and structural and functional characterization of the product and process, through to commercial scale production in full GMP compliance, makes the company an ideal partner for companies that lack the in-house expertise and assets necessary to carry out product development and commercial scale production.